A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications.

Bill 118 s 4878, also known as the "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications," aims to make changes to the process of approving generic drugs in the United States.

The bill proposes amendments to the Federal Food, Drug, and Cosmetic Act, specifically focusing on the approval of abbreviated new drug applications (ANDAs). ANDAs are applications submitted by pharmaceutical companies seeking approval to market generic versions of existing brand-name drugs.

The main goal of the bill is to streamline and expedite the approval process for generic drugs, ultimately increasing competition in the pharmaceutical market and potentially lowering drug prices for consumers. The specifics of the proposed amendments are not detailed in the summary, but it is clear that the bill seeks to make significant changes to the current regulatory framework governing generic drug approval. Overall, Bill 118 s 4878 represents an effort to improve access to affordable medications for Americans by making it easier for generic drugs to come to market.